Skip to main content
. Author manuscript; available in PMC: 2015 Jan 26.
Published in final edited form as: J Surg Res. 2013 Jun 29;185(2):e101–e108. doi: 10.1016/j.jss.2013.06.011

Fig. 1.

Fig. 1

BALF pepsin concentrations among 100 lung transplant patients: AAT disease (AATD) (n = 7), bronchiolitis obliterans organizing pneumonia (BOOP) (n = 1), CF (n = 14), COPD (n = 38), IPF (n = 24), Jo-1 syndrome (n = 1), lymphangioleiomyomatosis (LAM) (n = 1), pulmonary artery hypertension (PAH) (n = 2), pulmonary veno-occlusive disease (n = 1), sarcoidosis (n = 4), scleroderma (n = 1), pulmonary fibrosis (PF) from work exposure (n = 1), rheumatoid arthritis RA (n = 1), dermatomyositis (n = 1), polymyositis (n = 2), and pneumoconiosis (n = 1). The BALF pepsin concentrations were highest in those with IPF.